I want to clarify what was discussed in the previous episodes...
Todd Lee in his video is most likely referring to IGFBPs (Insulin-like Growth Factor Binding Proteins) — these are proteins that bind to IGF1 and regulate its activity in the body. Exogenous IGF1, taken externally (for example, through injections), may not have the same effect as growth hormone (GH), because growth hormone stimulates the production of endogenous IGF1 in the body, and this process depends on various factors, including the level of IGFBPs.
When you introduce exogenous IGF1, it may be metabolized more quickly or limited in its activity because it’s not transported or activated in the body as effectively as endogenous IGF1, which is produced in response to growth hormone. Exogenous IGF1 can also bind to IGFBPs, but if the level of these proteins in the body is insufficient or imbalanced, it can limit the effectiveness of IGF1.
Thus, Todd Lee suggests that IGFBPs are important for the proper transport and activation of IGF1, and it may be necessary to take into account their levels and role to achieve the same effect as high doses of growth hormone, which also stimulates the production of IGF1 through these proteins.
As for bypassing this issue, it could include:
- Using high doses of growth hormone, which stimulates the natural production of IGF1.
- Using supplements or drugs that may regulate or increase the level of IGFBPs to improve the transport and effectiveness of IGF1.
Therefore, the question is how to structure the experiment in such a way as to use exogenous IGF1 with maximum effectiveness, considering the necessity of IGFBPs for its proper functioning.